BioSpace News Archive

ABIONYX Pharma reported positive interim results of an open-label Phase 2a clinical trial evaluating CER-001 as a treatment for septic patients at high risk of developing Acute Kidney Injury.

Emergex Vaccines Holding Limited, a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program.

Meiji Seika Pharma Co., Ltd. announced that the first patient was dosed in Phase II clinical trial of ME3183, a selective phosphodiesterase-4 inhibitor, in patients with plaque psoriasis in the United States and Canada.

PureTech Health plc plans to publish its annual report and financial results on Tuesday, April 26, 2022 at 2:00 AM EDT / 7:00 AM BST.

Hansa Biopharma AB “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced the release of the Annual Report 2021

Biophytis SA provides an update on its most advanced clinical studies.

Biophytis SA announces its non audited financial results for the year ended December 31, 2021, and provides updates on key operational achievements as well as perspectives for 2022.

Zealand Pharma A/S announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, announced the presentation of new preclinical data for its lead program IMT-07 with product candidate OMX-0407, a first-in-class oral SIK3 inhibitor.

Axol Bioscience Ltd. announced that it has raised £3.2 million GBP in the extension of its previous funding round, bringing the total raised to £7 million GBP.